Skip to main content
×
×
Home

Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran

  • Aliasghar Ahmad Kia Daliri (a1), Hassan Haghparast (a2) and Jahanara Mamikhani (a3)
Abstract

Objective: The aim of this study was to assess the incremental cost-effectiveness of on-demand versus prophylactic hemophilia therapy in Iran from a third-party payers’ perspective.

Methods: A retrospective chart review of twenty-five type A hemophiliacs who were treated in three hemophilia treatment centers was conducted. The patients were boys 0–9 years old receiving one of two treatments: (i) prophylaxis with concentrate at clinic; (ii) concentrate at clinic as on-demand. Fourteen boys received on-demand infusions for bleeding events, and eleven boys received infusions prophylaxis. Data were extracted from documents in the hemophilia treatment centers during a period of approximately 6 months.

Results: The patients receiving prophylactic treatment had fewer bleeding events each month (mean, 0.26 versus 2.74) but used more concentrate (225.31 versus 87.20 units/kg per month). Average monthly cost per patient in the prophylaxis group was approximately 1.9 times higher than in the on-demand group. Compared with on-demand infusion, prophylaxis costs 3,201,656 Rials (€213.45) per bleeding event prevented.

Conclusion: Prophylactic care markedly reduces the number of bleeding episodes, but at considerable cost.

Copyright
References
Hide All
1. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994;236:391399.
2. Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia:summary statement. Haemophilia. 2003;9 (Suppl 1):14.
3. European Commission. Proceedings of Blood Safety in the European Community: An Initiative for Optimal Use; 20–22 May 1999; Wildbad Kreuth. Langen: Paul-Ehrlich Institute; 1999.
4. Globe DR, Curtis RG, Koerper MA. Utilization of care in haemophilia: a resource- based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia. 2004;10 (Suppl 1):6370.
5. Iranian Haemophilia Society's Report. Tehran, Iran; 2007.
6. Karimi M, Rahmani S, Ardeshiri R, et al. Cost of care in Iranian hemophilic patients. Iran Red Crescent Med J. 2007;9:154157.
7. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol. 1996;92:973978.
8. Lippert B, Berger K, Berntorp E, et al. Cost effectiveness of haemophilia treatment: A cross-national assessment. Blood Coagul Fibrinolysis. 2005;16:477485.
9. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535544.
10. Martines-Murillo C, Quintana S, Ambriz R, et al. An economic model of haemophilia in Mexico. Haemophilia. 2004;10:917.
11. Miners AH, Sabin CA, Tolley KH, et al. A Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med. 1998;244:515522.
12. Miners AH, Sabin CA, Tolley KH, et al. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics. 2002;20:759774.
13. Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:2532.
14. Smith PS, Teutsch SM, Shaffer PA, et al. Episodic versus prophylactic infusions for hemophilia A: A cost-effectiveness analysis. J Pediatrics. 1996;129:424431.
15. Szucs TD, Offner A, Schramm W. Socioeconomic impact of haemophilia care: Results of a pilot study. Haemophilia. 1996;2:211217.
16. United Kingdom Haemophilia Centre Directors Organization Executive Committee. Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. Haemophilia. 1997;3:6377.
17. Van Den Berg HM, Fischer K, Van Der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia. 2003;9 (Suppl 1):2731.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 1
Total number of PDF views: 23 *
Loading metrics...

Abstract views

Total abstract views: 953 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 16th December 2017. This data will be updated every 24 hours.